Immune Checkpoint Inhibitor–Associated Diabetes: A Single-Institution Experience

Retrospective chart review of 18 patients with new-onset immune checkpoint inhibitor–associated diabetes mellitus, found that this adverse effect presents abruptly, appears irreversible and is characterised by pancreatic atrophy.

Source:

Diabetes Care